Gujarat Kidney IPO Analyzed

The Gujarat Kidney and Super Speciality healthcare company is offering shares to the public for the first time. This means they are selling parts of their company to raise money. Investors can apply to buy these shares from December 22nd to December 24th, 2025.

Key Points

• Company: Gujarat Kidney and Super Speciality.
• What’s Offered: Shares available for purchase (IPO).
• Price Range: ₹108 to ₹114 per share.
• Minimum Buy: 128 shares per “lot”.
• Dates: Open December 22nd – 24th, listing December 30th.
• Uses of Funds: Hospitals, equipment, and potential acquisitions.
• Risk: Potential delays in projects and lease agreements.

This IPO is like the company asking people to invest in their future. They want to use the money to build new hospitals, buy equipment, and even buy other healthcare businesses. The shares will be sold in “lots,” which are groups of shares, and the minimum you can buy is 128 shares.

The price of the shares will be between ₹108 and ₹114. If you buy the shares, they will be listed on the stock market on December 30th, 2025, meaning you can sell them to other investors.

However, there are some risks to consider. The company plans to buy hospitals and other medical centers, and if these deals take longer than expected, it could affect the company’s plans. They are also building new hospitals, which can be complicated and expensive.

The money raised from the IPO will be used for specific things: ₹77 crore for acquiring Parekhs Hospital, ₹12.4 crore for Ashwini Medical Centre, ₹10.78 crore for Harmony Medicare, ₹30.09 crore for a new hospital in Vadodara, ₹6.82 crore for robotics equipment, and ₹1.2 crore for paying back loans. The rest will be used for general business purposes.

One important thing to remember is that the company is new to building hospitals from scratch (called “greenfield projects”). This means they don’t have a lot of experience, and these projects can be tricky. Also, some of the hospitals are on rented land, which adds another layer of risk because the company needs to agree on terms with the landlord.

Because the company recently bought Harmony Medicare, the financial information about the company is changing. Investors should be aware that the financial reports may not be easily compared to future reports.

Takeaway: Investing in this IPO involves supporting a company with ambitious growth plans, but it also carries risks associated with healthcare project development and potential delays.